Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 4
1982 21
1983 47
1984 49
1985 47
1986 46
1987 45
1988 73
1989 90
1990 56
1991 47
1992 46
1993 33
1994 45
1995 38
1996 38
1997 42
1998 43
1999 62
2000 78
2001 128
2002 169
2003 189
2004 194
2005 249
2006 315
2007 386
2008 582
2009 671
2010 804
2011 792
2012 909
2013 877
2014 992
2015 1124
2016 1196
2017 1240
2018 1263
2019 679
2020 19
Text availability
Article attribute
Article type
Publication date

Search Results

11,959 results
Results by year
Filters applied: . Clear all
Page 1
Monoclonal antibodies: formulations of marketed products and recent advances in novel delivery system.
Cui Y, et al. Drug Dev Ind Pharm 2017 - Review. PMID 28049357
Monoclonal antibodies (mAbs) are extensively employed for disease diagnosis and treatment because of their high homogeneity and antigen specificity. ...
Monoclonal antibodies (mAbs) are extensively employed for disease diagnosis and treatment because of their high homogeneity and antig …
CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies
Bacac M, et al. Clin Cancer Res 2018. PMID 29716920 Free article.
Purpose: Despite promising clinical activity, T-cell-engaging therapies including T-cell bispecific antibodies (TCB) are associated with severe side effects requiring the use of step-up-dosing (SUD) regimens to mitigate safety. ...CD20-TCB displays considerably higher potency than other CD20-TCB antibodies in clinical development and is efficacious on tumor cells expressing low levels of CD20. ...
Purpose: Despite promising clinical activity, T-cell-engaging therapies including T-cell bispecific antibodies (TCB) are associated w …
11,959 results
Jump to page
Feedback